Maharashtra may get supply of ‘Covishield’ only after May 20, says Rajesh Tope
Updated:
Updated:
April 27, 2021 16:50 IST
Rajesh Tope said Maharashtra alone needs 12 crore vaccine vials to inoculate the population of 5.71 crore in the age group of 18 to 44.
Share Article
AAA
Maharashtra Health Minister Rajesh Tope on April 27, 2021 said the state may receive its supply of ‘Covishield’ vaccine only after May 20.
| Photo Credit:
M. Periasamy
Rajesh Tope said Maharashtra alone needs 12 crore vaccine vials to inoculate the population of 5.71 crore in the age group of 18 to 44. Maharashtra Health Minister Rajesh Tope on Tuesday said the state may receive its supply of ‘Covishield’ vaccine only after May 20.
Coronavirus | ICMR issues FAQs for patients with hypertension, diabetes and heart diseases
April 27, 2021 19:03 IST
Updated:
April 27, 2021 19:03 IST
Updated:
Medications to control cholesterol (statins) should be continued, says ICMR.
Share Article
AAA
People wait at a centre for the coronavirus test during the weeklong lockdown in New Delhi on April 27, 2021.
| Photo Credit: Sushil Kumar Verma
Medications to control cholesterol (statins) should be continued, says ICMR.
Are patients with heart disease, diabetes or hypertension at increased risk to get coronavirus infection?
No, people with hypertension, diabetes or heart diseases are at no greater risk of getting the infection than anyone else.
Among people with above diseases is there an increased risk of severe illness or complications once infected?
Gujarat High Court reprimands State government
Updated:
Updated:
Court seeks detailed affidavit on steps being taken to control the pandemic
Share Article
Court seeks detailed affidavit on steps being taken to control the pandemic
The Gujarat High Court has again reprimanded the State government over its handling of the COVID-19 situation in the State. The court said the government was trying to paint a rosy picture while the reality was different.
A Division Bench, hearing the suo motu public interest litigation on the COVID-19 situation, noted that people were dying outside hospitals as there were no doctors to attend the patients and the entire system lacked “transparency.”
A woman being vaccinated in Ahmedabad. | Reuters/Amit Dave On Saturday, the pharmaceutical company Bharat Biotech officially announced the sale prices for its Covid-19 vaccine, Covaxin. State governments will have to pay Rs 600 per dose while private hospitals will have to pay Rs 1,200 per dose. These prices, fixed far above the corresponding rates announced by the Serum Institute of India for its vaccine, Covishield, has surprised observers for many reasons.
The Serum Institute could cite royalty payments to the Swedish-Britsh firm AstraZeneca from which it has licensed its vaccine as a potential reason for higher prices. But Bharat Biotech does not have to pay any royalty for Covaxin. Covaxin is, in large measure, a product of publicly funded research in India.